White Cross Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.10 M
- Company Age 15 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth -1.67%
- Ebitda -1.67%
- Net Worth -269.91%
- Total Assets -1.43%
About White Cross Pharmaceuticals
White Cross Pharmaceuticals Private Limited (WCPPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 March 2009 and has a history of 15 years and 11 months. Its registered office is in Hyderabad, Telangana, India.
The Corporate was formerly known as Linus Trade Private Limited. The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ravi Gubbala, Veera Pechetti, and Satyanarayana Aila serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24233TG2009PTC062934
-
Company No.
062934
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
03 Mar 2009
-
Date of AGM
21 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at White Cross Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravi Gubbala
|
Director | 03-Mar-2009 | Current |
|
Veera Pechetti
|
Director | 03-Mar-2009 | Current |
|
Satyanarayana Aila
|
Director | 01-Dec-2010 | Current |
Financial Performance of White Cross Pharmaceuticals.
White Cross Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 1.67% decrease in profit. The company's net worth observed a substantial decline by a decrease of 269.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of White Cross Pharmaceuticals?
In 2017, White Cross Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Matrix Formulations Private LimitedRavi Gubbala and Satyanarayana Aila are mutual person
-
Nextware Solutions Private Limited
Ravi Gubbala and Veera Pechetti are mutual person
-
Alekhya Power Private Limited
Ravi Gubbala is a mutual person
-
Matrixtakeda Pharma Private Limited
Satyanarayana Aila is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at White Cross Pharmaceuticals?
Unlock and access historical data on people associated with White Cross Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of White Cross Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped White Cross Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
